Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BTMDNASDAQ:KODNASDAQ:PMVPNYSE:PRME On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBTMDbiote$3.78-4.3%$3.64$3.04▼$8.44$206.80M1.16191,350 shs75,580 shsKODKodiak Sciences$3.88+5.4%$3.59$1.92▼$11.60$204.72M2.27348,602 shs277,777 shsPMVPPMV Pharmaceuticals$1.08-0.9%$0.96$0.81▼$1.82$56.11M1.43226,522 shs176,835 shsPRMEPrime Medicine$1.46$1.40$1.11▼$7.07$191.69M1.561.38 million shs1.16 million shs12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBTMDbiote0.00%-1.31%-5.97%+0.53%-42.99%KODKodiak Sciences0.00%-8.06%+16.52%+6.59%+39.07%PMVPPMV Pharmaceuticals0.00%+11.34%+28.86%-14.29%-38.98%PRMEPrime Medicine0.00%-13.61%+15.87%-18.44%-80.99%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBTMDbiote3.8417 of 5 stars3.54.00.00.03.53.31.3KODKodiak Sciences4.2114 of 5 stars3.04.00.04.61.23.30.6PMVPPMV Pharmaceuticals2.4042 of 5 stars3.52.00.00.02.71.70.6PRMEPrime Medicine4.0048 of 5 stars4.41.00.00.04.25.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBTMDbiote 3.00Buy$8.00111.64% UpsideKODKodiak Sciences 2.00Hold$9.00131.96% UpsidePMVPPMV Pharmaceuticals 3.00Buy$5.50409.26% UpsidePRMEPrime Medicine 2.75Moderate Buy$10.08590.64% UpsideCurrent Analyst Ratings BreakdownLatest PMVP, PRME, KOD, and BTMD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/27/2025PRMEPrime MedicineCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$10.00 ➝ $1.505/20/2025PRMEPrime MedicineJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetMarket Outperform ➝ Market Outperform$10.00 ➝ $6.005/20/2025PRMEPrime MedicineHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral5/20/2025PRMEPrime MedicineJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Neutral5/19/2025PRMEPrime MedicineChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$16.00 ➝ $12.003/31/2025KODKodiak SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$3.00 ➝ $3.003/20/2025PMVPPMV PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.003/20/2025PRMEPrime MedicineChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$15.00 ➝ $16.003/19/2025PRMEPrime MedicineHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.003/18/2025PRMEPrime MedicineWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$12.00 ➝ $13.00(Data available from 6/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBTMDbiote$199.38M1.04$0.39 per share9.60($0.58) per share-6.52KODKodiak SciencesN/AN/AN/AN/A$5.07 per shareN/APMVPPMV PharmaceuticalsN/AN/AN/AN/A$4.41 per shareN/APRMEPrime Medicine$3.85M49.84N/AN/A$1.37 per share1.07Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBTMDbiote$3.32M$0.6114.547.00N/A5.20%-32.41%22.26%8/6/2025 (Estimated)KODKodiak Sciences-$260.49M-$3.63N/AN/AN/AN/A-84.52%-45.40%8/13/2025 (Estimated)PMVPPMV Pharmaceuticals-$68.96M-$1.18N/AN/AN/AN/A-24.20%-21.67%8/6/2025 (Estimated)PRMEPrime Medicine-$198.13M-$1.61N/AN/AN/AN/A-107.87%-74.97%N/ALatest PMVP, PRME, KOD, and BTMD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025KODKodiak Sciences-$0.89-$1.09-$0.20-$1.09N/AN/A5/9/2025Q1 2025PMVPPMV Pharmaceuticals-$0.37-$0.34+$0.03-$0.34N/AN/A5/7/2025Q1 2025BTMDbiote$0.06$0.08+$0.02$0.37$47.25 million$48.99 million3/27/2025Q4 2024KODKodiak Sciences-$0.90-$0.84+$0.06-$0.84N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBTMDbioteN/AN/AN/AN/AN/AKODKodiak SciencesN/AN/AN/AN/AN/APMVPPMV PharmaceuticalsN/AN/AN/AN/AN/APRMEPrime Medicine$1.4599.04%N/AN/A N/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBTMDbioteN/A1.501.16KODKodiak SciencesN/A8.428.42PMVPPMV PharmaceuticalsN/A13.9813.98PRMEPrime MedicineN/A6.506.50Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBTMDbiote21.68%KODKodiak Sciences89.06%PMVPPMV Pharmaceuticals90.20%PRMEPrime Medicine70.37%Insider OwnershipCompanyInsider OwnershipBTMDbiote24.00%KODKodiak Sciences45.90%PMVPPMV Pharmaceuticals7.57%PRMEPrime Medicine22.93%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBTMDbiote19454.71 million46.78 millionNot OptionableKODKodiak Sciences9052.76 million28.79 millionOptionablePMVPPMV Pharmaceuticals5051.95 million47.81 millionOptionablePRMEPrime Medicine234131.29 million100.38 millionOptionablePMVP, PRME, KOD, and BTMD HeadlinesRecent News About These CompaniesInsider Buying: Prime Medicine, Inc. (NYSE:PRME) Major Shareholder Acquires 21,000 Shares of StockJune 13 at 8:44 AM | insidertrades.comPrime Medicine, Inc. (NYSE:PRME) Major Shareholder Acquires $33,600.00 in StockJune 12 at 5:38 PM | marketbeat.comTwo Sigma Investments LP Sells 152,374 Shares of Prime Medicine, Inc. (NYSE:PRME)June 10, 2025 | marketbeat.comPrime Medicine, Inc. (NYSE:PRME) Given Consensus Recommendation of "Moderate Buy" by BrokeragesJune 4, 2025 | marketbeat.comMillennium Management LLC Reduces Stake in Prime Medicine, Inc. (NYSE:PRME)May 30, 2025 | marketbeat.comPrime Medicine to Participate in Upcoming Investor ConferencesMay 29, 2025 | globenewswire.comPrime Medicine's (PRME) "Neutral" Rating Reaffirmed at CitigroupMay 28, 2025 | marketbeat.comCitigroup Downgrades Prime Medicine (PRME)May 28, 2025 | msn.comCiti Downgrades Prime Medicine (PRME) to Neutral, Cuts PT to $1.50 Due to Market UncertaintyMay 27, 2025 | msn.comChardan Capital Raises Earnings Estimates for Prime MedicineMay 25, 2025 | marketbeat.comHC Wainwright Lowers Earnings Estimates for Prime MedicineMay 24, 2025 | marketbeat.comWedbush Has Bullish Estimate for Prime Medicine Q3 EarningsMay 23, 2025 | marketbeat.comWestwood Holdings Group Inc. Increases Stake in Prime Medicine, Inc. (NYSE:PRME)May 23, 2025 | marketbeat.comPrime Medicine (NYSE:PRME) Downgraded to "Neutral" Rating by HC WainwrightMay 22, 2025 | marketbeat.comPrime Medicine's (PRME) Neutral Rating Reaffirmed at JPMorgan Chase & Co.May 22, 2025 | marketbeat.com6 Analysts Assess Prime Medicine: What You Need To KnowMay 21, 2025 | nasdaq.comCEO among 25% of staff out the door at cash-strapped PrimeMay 20, 2025 | thepharmaletter.comPrime Medicine CEO exits as biotech shelves sole clinical gene therapy, lays off 25% of staffMay 20, 2025 | fiercebiotech.comPrime Medicine claims ‘proof of concept,’ but lays off staff in pivotMay 20, 2025 | biopharmadive.comCRISPR pioneer Prime Medicine switches CEO and lays off quarter of its staffMay 20, 2025 | bostonglobe.comPrime Medicine drops after cutting CGD program amid restructuringMay 20, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePMVP, PRME, KOD, and BTMD Company Descriptionsbiote NASDAQ:BTMD$3.78 -0.17 (-4.30%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$3.79 +0.01 (+0.26%) As of 06/13/2025 04:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support. It also sells dietary supplements under the Biote brand; and sterile pellet insertion kits that is used with hormone optimization therapies for male and female. The company was founded in 2012 and is headquartered in Irving, Texas.Kodiak Sciences NASDAQ:KOD$3.88 +0.20 (+5.43%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$4.03 +0.15 (+3.87%) As of 06/13/2025 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.PMV Pharmaceuticals NASDAQ:PMVP$1.08 -0.01 (-0.92%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$1.08 0.00 (0.00%) As of 06/13/2025 04:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is based in Princeton, New Jersey.Prime Medicine NYSE:PRME$1.46 0.00 (0.00%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$1.49 +0.03 (+2.05%) As of 06/13/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. It has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. The company was incorporated in 2019 and is based in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/09 - 06/13 Alphabet Enters a Bull Market: Is It Time to Buy? Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Ignore the Noise—Samsara Stock Is Still a Strong Buy Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
